{
    "clinical_study": {
        "@rank": "127716", 
        "arm_group": [
            {
                "arm_group_label": "Renal Disease", 
                "arm_group_type": "Active Comparator", 
                "description": "Those with mild to moderate renal disease and had an EZ-IO for 48 hours"
            }, 
            {
                "arm_group_label": "Diabetes", 
                "arm_group_type": "Active Comparator", 
                "description": "Those with controlled diabetes and had an EZ-IO for 48 hours"
            }, 
            {
                "arm_group_label": "Renal disease and diabetes", 
                "arm_group_type": "Active Comparator", 
                "description": "Those with both mild to moderate renal disease and controlled diabetes  and had an EZ-IO for 48 hours"
            }
        ], 
        "brief_summary": {
            "textblock": "The objective for this study is to determine the safety of intraosseous (IO) access for a\n      period up to 48 hours evaluating health-compromised adult volunteers with diabetes or renal\n      disease.  The hypothesis is that there will be no serious complications for the subjects\n      during a 48 hours IO catheter dwell time."
        }, 
        "brief_title": "Continuous Intraosseous Vascular Access Over 48 Hours", 
        "completion_date": {
            "#text": "May 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Intraosseous Vascular Access", 
        "detailed_description": {
            "textblock": "The objective of this study is to determine the safety of intraosseous (IO) access for a\n      period up to 48 hours, in adult volunteer subjects with a history of being\n      health-compromised, including two subsets of subjects; those with mild to moderate renal\n      disease (National Health and Nutrition Examination Survey Stage 1 to 3) and patients with\n      controlled diabetes.  The hypothesis is that there will be no serious complications for the\n      subjects during a 48 hour IO catheter dwell time in either place."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  21 years or older Self Identifying as having poor vascular access Having one\n             criteria: Renal disease or diabetes\n\n        Exclusion Criteria:\n\n          -  Imprisoned Self identifying as pregnant Cognitively impaired Fracture in target bone\n             Excessive tissue and/or absence of adequated anatomical landmarks in target bone\n             Signs and symptoms of infection in target area IO insertion in past 48 hours\n             Intravenous infusion within the past 30 days Current use of anti-coagulants Previous\n             adverse reaction or known allergy to Lidocaine Previous adverse reaction to heparin\n             Current cardiac condition requiring pacemaker Currently taking beta blockers History\n             of bilateral lymph node dissection in the arms or legs Known sickle-cell disease"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "21 Years"
        }, 
        "enrollment": {
            "#text": "120", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 28, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01866475", 
            "org_study_id": "2011-16"
        }, 
        "intervention": {
            "arm_group_label": [
                "Renal Disease", 
                "Diabetes", 
                "Renal disease and diabetes"
            ], 
            "description": "To have an EZ-IO placed up to 48 hours", 
            "intervention_name": "EZ-IO", 
            "intervention_type": "Device"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "IO", 
            "Intraosseous", 
            "EZ-IO"
        ], 
        "lastchanged_date": "December 12, 2013", 
        "number_of_arms": "3", 
        "official_title": "A Study to Determine the Safety of Continuous Intraosseous Vascular Access Over a Period of 48 Hours", 
        "overall_official": {
            "affiliation": "Vidacare Corporation", 
            "last_name": "Larry J Miller, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Enrolling by invitation", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "May 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Presence of complications from 48 hour intraosseous vascular access using EZ-IO.", 
            "measure": "Complications from intraosseous access", 
            "safety_issue": "Yes", 
            "time_frame": "48 hours"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01866475"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Vidacare Corporation", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Vidacare Corporation", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}